A study to investigate the safety, tolerability, and efficacy of SAR446268, an adeno-associated viral vector-mediated gene therapy in participants aged 10 to 50 years of age with non-congenital myotonic dystrophy type 1

Trial Identifier: DFI17808
Sponsor: Sanofi
Start Date: July 2025
Primary Completion Date: February 2029
Study Completion Date: February 2029
Condition: Muscular Dystrophy

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
ARGENTINA, Buenos Aires BUENOS AIRES, Buenos Aires, ARGENTINA, 1181
AUSTRALIA, Queensland BRISBANE, Queensland, AUSTRALIA, 4029
CANADA, Quebec MONTREAL, Quebec, CANADA, H3A 2B4
ISRAEL RAMAT GAN, ISRAEL, 5262100
UNITED KINGDOM, Newcastle upon Tyne NEWCASTLE UPON TYNE, Newcastle upon Tyne, UNITED KINGDOM, NE7 7DN
UNITED STATES, Florida GAINESVILLE, Florida, UNITED STATES, 32601
UNITED STATES, Florida TAMPA, Florida, UNITED STATES, 33612
UNITED STATES, New York NEW YORK, New York, UNITED STATES, 10032